- $2.64bn
- $2.63bn
- $750.27m
- 91
- 19
- 92
- 75
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.06 | ||
| PEG Ratio (f) | 0.27 | ||
| EPS Growth (f) | 169.84% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.47 | ||
| Price to Tang. Book | 13.56 | ||
| Price to Free Cashflow | 32.02 | ||
| Price to Sales | 3.52 | ||
| EV to EBITDA | 34.25 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.12% | ||
| Return on Equity | -1.12% | ||
| Operating Margin | -4.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 388.22 | 550.7 | 745.42 | 766.55 | 750.26 | 800.99 | 859.7 | 24.63% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +51.42 | n/a | n/a | n/a | n/a | +656.7 | +22.62 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GoodRx Holdings, Inc. provides a consumer-focused digital healthcare platform in the United States. It offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. It also equips healthcare professionals to find and prescribe affordable medications. It offers information and tools to help consumers compare prices and save on their prescription drug purchases. It operates a price comparison platform that provides consumers with geographically relevant prescription pricing and provides access to negotiated prices through its codes that can be used to save money on prescriptions across the United States (the prescription transactions offering). It also offers other healthcare products and services, including pharmaceutical manufacturer solutions, subscriptions, and telehealth services. Its subscription offerings provide additional benefits to consumers of its prescription transactions offering.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 3rd, 2015
- Public Since
- September 23rd, 2020
- No. of Shareholders
- 7
- No. of Employees
- 694
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 394,997,372
- Address
- 2701 Olympic Boulevard, Suite 990, SANTA MONICA, 90404
- Web
- https://investors.goodrx.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Latest News for GDRX
Upcoming Events for GDRX
Q1 2024 GoodRx Holdings Inc Earnings Call
Q1 2024 GoodRx Holdings Inc Earnings Release
Goodrx Holdings Inc Annual Shareholders Meeting
Q2 2024 GoodRx Holdings Inc Earnings Release
Similar to GDRX
2U
NASDAQ Global Select Market
ACV Auctions
NASDAQ Global Select Market
Adeia
NASDAQ Global Select Market
Adobe
NASDAQ Global Select Market
Agilysys
NASDAQ Global Select Market
FAQ
As of Today at 19:09 UTC, shares in Goodrx Holdings are trading at $6.69. This share price information is delayed by 15 minutes.
Shares in Goodrx Holdings last closed at $6.69 and the price had moved by +16.96% over the past 365 days. In terms of relative price strength the Goodrx Holdings share price has underperformed the S&P500 Index by -2.67% over the past year.
The overall consensus recommendation for Goodrx Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Goodrx Holdings does not currently pay a dividend.
Goodrx Holdings does not currently pay a dividend.
Goodrx Holdings does not currently pay a dividend.
To buy shares in Goodrx Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.69, shares in Goodrx Holdings had a market capitalisation of $2.64bn.
Here are the trading details for Goodrx Holdings:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GDRX
Based on an overall assessment of its quality, value and momentum Goodrx Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Goodrx Holdings is $8.76. That is 30.94% above the last closing price of $6.69.
Analysts covering Goodrx Holdings currently have a consensus Earnings Per Share (EPS) forecast of $0.37 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Goodrx Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +3.45%.
As of the last closing price of $6.69, shares in Goodrx Holdings were trading +5.44% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Goodrx Holdings PE ratio based on its reported earnings over the past 12 months is 17.06. The shares last closed at $6.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Goodrx Holdings' directors